For the quarter ending 2026-03-31, COCH made $39K in revenue. -$5,701K in net income. Net profit margin of -14617.95%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | 39 | 75 | 42 | 78 |
| Cost of goods sold | 313 | 211 | 203 | 234 |
| Research and development | 3,642 | 4,553 | 2,700 | 2,485 |
| Sales and marketing | 164 | 96 | 405 | 361 |
| General and administrative | 1,879 | 1,600 | 2,442 | 2,068 |
| Total costs and operating expenses | 5,998 | 6,460 | 5,750 | 5,148 |
| Change in fair value of forward purchase agreement put option liability | - | - | - | 0 |
| Operating loss | -5,959 | -6,385 | -5,708 | -5,070 |
| Change in fair value of forward purchase agreement warrant liability | 13 | -12 | -64 | -37 |
| Change in fair value of forward purchase agreement warrant liability due to extension | - | 6* | - | - |
| Change in fair value of private warrant liability | - | - | 339 | - |
| Loss on offering and change in fair value of private warrant liability | -2,005 | 173* | - | - |
| Change in fair value of publicly traded warrant liability | 390 | 18 | 33 | 32 |
| Other income (expense), net | 6 | -16 | 5 | -1 |
| Interest expense (related party) | 0 | 0 | 471 | 624 |
| Total other income (expense), net | 1,608 | -201 | -774 | -620 |
| Net loss | -4,351 | -6,586 | -6,482 | -5,690 |
| Cumulative preferred dividends | 1,350 | 1,151 | 1,265 | 1,252 |
| Net loss attributable to common stockholders, basic | -5,701 | -7,737 | -7,747 | -6,942 |
| Basic EPS | -0.08 | -0.272 | -0.35 | -0.32 |
| Diluted EPS | -0.08 | -0.272 | -0.35 | -0.32 |
| Basic Average Shares | 68,934,960 | 28,476,325 | 21,851,606 | 21,383,852 |
| Diluted Average Shares | 68,934,960 | 28,476,325 | 21,851,606 | 21,383,852 |
Envoy Medical, Inc. (COCH)
Envoy Medical, Inc. (COCH)